INmune Bio receives its first patent covering INKmune therapy

INKmune is an experimental biologic delivery system that allows for the delivery of essential priming signals to patients’ resting NK cells. INKmune is delivered by a simple IV infusion. Once in the patient’s system, INKmune comes in contact with resting NK cells. The interaction converts resting NK cells to “primed NK cells” (PiNKs) similar to an “on-off” switch. PiNKs then remain primed until they contact and kill cancer cells. 

Natural killer cells are an important component of the immune system. INKmune enhances a patient’s own NK cells to more efficiently recognize and combat the proliferation of cancer.